10/15/2026
New research is offering a closer look at how Lewy body dementia (LBD) may be identified. š§
A Cleveland Clinic study found that a biomarker called α-synuclein, measured in cerebrospinal fluid, was detected in 72% of people with clinically diagnosed LBD compared with 4% of healthy participants.
While more research is needed, these findings may help advance our understanding of Lewy body dementia and improve how it is diagnosed.
Read the full story through the link below.
https://consultqd.clevelandclinic.org/csf-alpha-synuclein-biomarker-strongly-associated-with-clinical-features-of-dementia-with-lewy-bodies